Brief: Revelation Biosciences Announces Phase 1 Clinical Study Of Gemini Met The Primary Safety Endpoint And Showed Statistically Significant Biomarker Activity
24/06/2024 15:45
June 24 (Reuters) - Revelation Biosciences Inc REVB.O :
* REVELATION BIOSCIENCES ANNOUNCES PHASE 1 CLINICAL STUDY OF
GEMINI MET THE PRIMARY SAFETY ENDPOINT AND SHOWED STATISTICALLY
SIGNIFICANT BIOMARKER ACTIVITY
* REVELATION BIOSCIENCES INC - GEMINI WAS SAFE AND WELL
TOLERATED
AT PHARMACOLOGICALLY ACTIVE DOSES-
* REVELATION BIOSCIENCES INC - GEMINI ADMINISTRATION INDUCED
STATISTICALLY SIGNIFICANT, DOSE DEPENDENT CHANGES IN KEY
BIOMARKERS OF ACTIVITY
Source text for Eikon: ID:nBw5rGj67a
Further company coverage: REVB.O
((Reuters.Briefs@thomsonreuters.com;))